Picture Berlin Partner BIO 2025 International Convention Boston 650x100px

Product › Details

venture capital

	Next higher product group	private equity

Record changed: 2025-06-05

More documents for venture capital

[1] SpliceBio S.L.. (6/11/25). "Press Release: SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines". Barcelona....
[2] GlycoEra AG. (5/27/25). "Press Release: GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases". Newton, MA & Wädenswil....
[3] ReproNovo SA. (5/21/25). "Press Release: ReproNovo Raises $65 Million Series A Financing to Advance Phase 2 Clinical Trials of Novel Therapies in Reproductive Medicine and Women’s Health". Lausanne & Copenhagen....
[4] Azafaros B.V.. (5/13/25). "Press Release: Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders". Leiden....
[5] Quidditas S.A.. (5/11/25). "Press Release: Quidditas Raises €2.62M to Accelerate Development of Pioneering Genome Editing Technology". Liège....
[6] Haya Therapeutics SA. (5/8/25). "Press Release: Haya Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases". Lausanne & San Diego, CA....
[7] Nuevocor. (5/6/25). "Press Release: Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy". Singapore & Philadelphia, PA....
[8] Deepull Diagnostics S.L.. (4/29/25). "Press Release: Deepull Secures Oversubscribed €50 million Series C Financing to Advance UllCore Diagnostic System for Direct-from-Blood Rapid Pathogen Detection". Barcelona....
[9] Granite Bio AG. (4/24/25). "Press Release: Granite Bio Debuts with $100 Million of Capital". Basel & San Francisco, CA....
[10] Glycomine, Inc.. (4/16/25). "Press Release: Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG". San Carlos, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)